Functional characterization of small and large alveolar macrophages in sarcoidosis and idiopathic pulmonary fibrosis compared with non-fibrosis interstitial lung diseases
CONCLUSION: A relevant potential of the activation and adhesion markers as well as oxidative burst activity expressed on small and large AMs, in the perspective of differential diagnosis of sarcoidosis and IPF.PMID:37574726 | DOI:10.3233/HAB-230005
Source: Human Antibodies - August 14, 2023 Category: Biochemistry Authors: Sara El Fakihi Aicha El Allam Hicham Tahoune Nouhaila Najimi Chaimae Kadi Azeddine Ibrahimi Jamal-Eddine Bourkadi Fouad Seghrouchni Source Type: research

Tumefactive brain parenchymal neurosarcoidosis
ConclusionTumefactive brain parenchymal lesions are uncommon, usually affect the supratentorial brain along with leptomeningitis, and are refractory to initial treatments with a high risk of relapse. Significant sequelae were encountered despite a favorable median last mRS.
Source: Journal of Neurology - August 12, 2023 Category: Neurology Source Type: research

Clinical Response to Tumor Necrosis Factor- α Inhibitor Therapy in the Management of Cardiac Sarcoidosis
This study aimed to evaluate the disease course of patients with CS treated with either infliximab or adalimumab the rapy based on serial 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging and clinical outcomes. An institutional CS research database was queried for patients treated with TNF-α inhibitors between 2016 and 2021.
Source: The American Journal of Cardiology - August 12, 2023 Category: Cardiology Authors: Robert Churchill, Daniel Sykora, Matteo Castrichini, Courtney Arment, Elena Myasoedova, Mohamed Elwazir, John Bois, Kathleen Young, Andrew Rosenbaum Source Type: research

Sarcoidosis
cgk18@duke.eduWed, 08/09/2023 - 08:14 Treatment PageSarcoidosis Order Providers ManuallyHakim Azfar Ali, MDRavi Karra, MD, MHSJohana Rocio Fajardo, DNP, ANP-BC, FHFSA, CHFNAlbert Y. Sun, MDMichel G. Khouri, MDJayanth R. Doss, MD, MPHMatilda W. Nicholas, MD, PhDAnne Louise Marano, MDDilraj Grewal, MDCarolyn Glass, MD, PhDSuma Shah, MDElijah A. Lackey, MD
Source: dukehealth.org: Duke Health News - August 9, 2023 Category: Consumer Health News Authors: cgk18 at duke.edu Source Type: news

Incidence and Predictors of Relapse After Weaning Immune Suppressive Therapy in Cardiac Sarcoidosis
Sarcoidosis is a remitting-relapsing disease with a greatly variable course.1 The prevalence of cardiac involvement is estimated to be up to 25%.2,3 It has been well established that the presence of cardiac sarcoidosis is an indication for immune suppression.4 –6 Modern therapeutic strategies typically use an extended corticosteroid taper with a goal of fully suppressing the acute inflammatory process while avoiding unnecessarily high cumulative corticosteroid exposure and associated risk of adverse events.
Source: The American Journal of Cardiology - August 8, 2023 Category: Cardiology Authors: Kelly Arps, Jayanth Doss, Kelly Geiger, Karen Flores-Rosario, Adam D. DeVore, Ravi Karra, Han W. Kim, Jonathan P. Piccini, Sean D. Pokorney, Albert Y. Sun Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20